{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017748","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.331418+00:00","generated_at":"2026-06-02T23:38:47.502485+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric issues 458K shares at $0.94 to waive equity line restriction; no proceeds","bullets":["Issued 458,000 shares to institutional investors at $0.94 per share in registered direct offering.","Offering is to permanently waive variable rate transaction limitation from December 2023 Inducement Letters.","Company will not receive any net proceeds; waiver enables use of existing equity line of credit.","Company restricted from issuing additional shares for 30 days or until 15 million shares trade."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017748","json":"https://secwatch.observer/filing/0001493152-24-017748.json","markdown":"https://secwatch.observer/filing/0001493152-24-017748.md","text":"https://secwatch.observer/filing/0001493152-24-017748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/0001493152-24-017748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:38:47.502485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc37a80c23df37ac48f4829a6d2cffb741e97072","claim":"Enveric Biosciences, Inc. entered into Purchase Agreements with certain institutional investors valued at at a deemed offering price of $0.94 per share (effective 2024-05-03).","evidence_excerpt":"On May 3, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreements”) for the issuance in a registered direct offering of an aggregate of 458,000 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/0001493152-24-017748-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"at a deemed offering price of $0.94 per share"},{"label":"Effective","value":"2024-05-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}